Reticular
Reticular uses AI to help life-science teams discover biological drug candidates from limited experimental data. The company applies machine learning and small-data modeling techniques in biotechnology research to predict and optimize biological molecules. Reticular operates as a B2B AI-driven research partner for pharmaceutical and biotech teams, offering computational discovery workflows and model-driven hypothesis generation. Its platform accelerates early-stage discovery by enabling target nomination and candidate selection where traditional data volumes are scarce.
Reticular
Reticular uses AI to help life-science teams discover biological drug candidates from limited experimental data. The company applies machine learning and small-data modeling techniques in biotechnology research to predict and optimize biological molecules. Reticular operates as a B2B AI-driven research partner for pharmaceutical and biotech teams, offering computational discovery workflows and model-driven hypothesis generation. Its platform accelerates early-stage discovery by enabling target nomination and candidate selection where traditional data volumes are scarce.
TL;DR
Sector: AI-driven biotechnology (protein engineering and genetic screening)
Stage / Funding: Pre-seed; Y Combinator-backed; disclosed total funding $500,000 (USD)
Founders: Nithin Parsan and John Yang
Headquarters: San Francisco & Boston, United States
Tech focus: Interpretable and steerable machine learning for small-data biological discovery
Company Overview
Problem Domain
Biotechnology R&D bottlenecks in early-stage molecule discovery when experimental data are limited.
Founded
2024
Industry
Biotechnology
Tech Stack
Funding Track Record
500000
Investor Signal
“Backed by Y Combinator; public materials also list investors including CRV, BoxGroup, SV Angel and angel investors from frontier AI labs and biopharma”